BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting data on the company’s AKT inhibitor, ARQ 751, in two poster presentations at the 2019 ...
A $2.7 billion buyout offer is causing this biotech stock to take off. Merck liked what it saw with ArQule's promising pipeline candidate ARQ 531. The experimental drug is currently in a phase 2 ...
Kenilworth-based Merck announced on Thursday the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of ArQule Inc. at a purchase ...
Dec 9 (Reuters) - Merck & Co said on Monday it would buy cancer drug developer ArQule Inc in a $2.7 billion all-cash deal, bolstering its oncology franchise with the smaller rival's lead drug that is ...
BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced final results from the phase 1 study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both ...
The pharma company has wowed investors with solid clinical data multiple times this year. The clinical results announced to date need to be replicated in larger trials, but investors have reason to be ...
Kenilworth-based Merck and Burlington, Mass.- based ArQule Inc. announced Monday they have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ArQule for $20 per ...
ArQule and Daiichi Sankyo Announce Completion of Patient Recruitment in Phase 3 Clinical Trial of Tivantinib in Non-Small Cell Lung Cancer WOBURN, Mass. & TOKYO--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ...
(RTTNews) - Biopharmaceutical company Merck (MRK), known as MSD outside the U.S. and Canada, agreed Monday to acquire, through a subsidiary, its peer ArQule, Inc. (ARQL) for $20 per share in cash for ...
ArQule reported positive results from Part A of its phase 1/2 study using miransertib to treat patients with PIK3CA-related overgrowth spectrum and Proteus Syndrome. Based on the positive data, plus ...
Nes Ziona, Israel, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that Brian Schwartz, MD, who ...
Merck & Co. Inc. said Monday it has entered an agreement to acquire ArQule Inc. for $20 a share in cash or an equity value of about $2.7 billion. The deal is expected to close in the first quarter of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback